1.7 ML denosumab 70 MG/ML Injection [Xgeva]

What the CMS Formulary Data Shows for 1.7 ML denosumab 70 MG/ML Injection [Xgeva]

Per the CMS 2026 Part D formulary file, 1.7 ML denosumab 70 MG/ML Injection [Xgeva] (RxNorm concept RXCUI 1046402, generic name 1.7) appears on 47 distinct formulary files spanning 1,606 Medicare Part D plan offerings - 31.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.6.

Real-world access to 1.7 ML denosumab 70 MG/ML Injection [Xgeva] depends on utilization management as much as tier placement: 97.9% of covering formularies require prior authorization. 0% require step therapy. 57.4% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 2,900 Part D beneficiaries filled 1.7 ML denosumab 70 MG/ML Injection [Xgeva] in 2023, with total plan-and-beneficiary spending of $46,309,173 and an average per-beneficiary annual cost of $15,968.68. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 1.7 ML denosumab 70 MG/ML Injection [Xgeva] today.